The protein is implicated in a wide swath of cancers, but harnessing it for drug R&D is still a major scientific challenge.
Figure 8: Regulation of ALDH3A1 and NECTIN4 by p53. Researchers Jessica J. Miciak, Lucy Petrova, Rhythm Sajwan, Aditya Pandya, Mikayla Deckard, Andrew J. Munoz, and Fred Bunz from the Sidney Kimmel ...
Schematic illustrating the effects of p53C and M237I in driving the conversion of p63C and p73C droplets into amyloid aggregates at physiologically relevant temperatures. Heparin prevents the ...
A research team at the University of Konstanz, led by toxicologist Ivano Amelio, has demonstrated how differently individual mutations of the tumor suppressor p53 affect pancreatic carcinomas. When ...
Phase II study to evaluate surufatinib in patients with osteosarcoma and soft tissue sarcoma that has failed standard chemotherapy: Updated analysis. This is an ASCO Meeting Abstract from the 2024 ...
TP53 mutations are crucial in cancer development and treatment response, influenced by genetic and environmental factors. In CLL and AML, TP53 serves as a significant prognostic marker, affecting ...
Autologous T-Cell Therapies in Solid Tumor Malignancies: Current Landscape and Future Opportunities Histology-agnostic therapies: by focusing on common mutations across various cancers, this approach ...
Researchers at the University of Illinois Chicago have developed an anti-cancer therapy inspired by bacteria found in cancer tumors.When tested in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results